FY2020 EPS Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Lifted by Analyst

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Analysts at Cantor Fitzgerald raised their FY2020 EPS estimates for Neurocrine Biosciences in a note issued to investors on Tuesday, November 5th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will post earnings of $2.40 per share for the year, up from their previous estimate of $2.29.

Several other research firms have also issued reports on NBIX. Piper Jaffray Companies lifted their price target on shares of Neurocrine Biosciences from $111.00 to $116.00 in a report on Tuesday. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a report on Wednesday, July 31st. BidaskClub lowered shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a report on Friday, September 13th. Oppenheimer started coverage on shares of Neurocrine Biosciences in a report on Tuesday, July 16th. They issued an “outperform” rating and a $100.00 price target on the stock. Finally, CIBC started coverage on shares of Neurocrine Biosciences in a report on Tuesday, July 16th. They issued an “outperform” rating and a $100.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $106.11.

NASDAQ NBIX opened at $102.56 on Wednesday. The firm’s fifty day simple moving average is $95.39 and its two-hundred day simple moving average is $89.20. The company has a current ratio of 7.44, a quick ratio of 7.32 and a debt-to-equity ratio of 0.96. Neurocrine Biosciences has a 12-month low of $64.72 and a 12-month high of $111.00. The firm has a market capitalization of $9.49 billion, a P/E ratio of 466.18, a P/E/G ratio of 6.53 and a beta of 1.20.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.56 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.63 by ($0.07). Neurocrine Biosciences had a net margin of 2.98% and a return on equity of 0.46%. The business had revenue of $222.09 million for the quarter, compared to analysts’ expectations of $211.31 million. During the same period in the previous year, the business earned $0.52 earnings per share. The business’s quarterly revenue was up 46.3% compared to the same quarter last year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Comerica Bank lifted its position in Neurocrine Biosciences by 3.3% during the third quarter. Comerica Bank now owns 3,933 shares of the company’s stock valued at $386,000 after purchasing an additional 125 shares during the period. Nisa Investment Advisors LLC lifted its position in Neurocrine Biosciences by 2.2% during the third quarter. Nisa Investment Advisors LLC now owns 6,265 shares of the company’s stock valued at $565,000 after purchasing an additional 135 shares during the period. M&T Bank Corp lifted its position in Neurocrine Biosciences by 4.7% during the second quarter. M&T Bank Corp now owns 3,377 shares of the company’s stock valued at $286,000 after purchasing an additional 153 shares during the period. JGP Global Gestao de Recursos Ltda. lifted its position in Neurocrine Biosciences by 5.6% during the third quarter. JGP Global Gestao de Recursos Ltda. now owns 3,097 shares of the company’s stock valued at $279,000 after purchasing an additional 163 shares during the period. Finally, Virginia Retirement Systems ET AL lifted its position in Neurocrine Biosciences by 1.2% during the third quarter. Virginia Retirement Systems ET AL now owns 17,000 shares of the company’s stock valued at $1,532,000 after purchasing an additional 200 shares during the period. Institutional investors own 96.07% of the company’s stock.

In other news, insider Darin Lippoldt sold 3,264 shares of Neurocrine Biosciences stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $100.05, for a total transaction of $326,563.20. Following the completion of the sale, the insider now directly owns 21,625 shares in the company, valued at $2,163,581.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Dimitri E. Grigoriadis sold 10,188 shares of Neurocrine Biosciences stock in a transaction on Friday, November 1st. The stock was sold at an average price of $100.34, for a total transaction of $1,022,263.92. Following the sale, the insider now owns 118,596 shares of the company’s stock, valued at $11,899,922.64. The disclosure for this sale can be found here. Insiders have sold 37,795 shares of company stock valued at $3,681,988 over the last quarter. Insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Read More: Dogs of the Dow

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.